Safety Study of Flavocoxid in Duchenne Muscular Dystrophy

Summary

Objective of this study is to evaluate safety and tolerability of flavocoxid administered at the daily oral dose of 500 or 1000 mg/die for one year in DMD patients, alone or in association with steroids (deflazacort on alternate days) started at least one year before. The investigators will also perform a multidimensional clinical evaluation covering functional and muscle strength and quality of life (QoL)assessments.

Timeline

Start

2011-03

Primary completion

2013-12

Completion

2013-12

Drugs

Indications